Daniel C. Gibbons

1.2k citations

34 papers · 800 indexed · h-index 12

Impact in

Emergency Medicine top 5%
- Emergency and Acute Care Studies
Orthopedics and Sports Medicine top 10%

Papers in

Infectious Diseases 11
- SARS-CoV-2 and COVID-19 Research 11
- COVID-19 Clinical Research Studies 11
- SARS-CoV-2 detection and testing 4
Family Practice 1

Co-authors: Martin Rosendaal Astrid Hoebertz Isabel R. Orriss Timothy R. Arnett Sajeda Meghji Jennifer C. Utting Sharif Ismail Shamini Gnani
Journals: Familial Cancer (2 papers)BMC Infectious Diseases (2 papers)Infection (2 papers)British Journal of General Practice (2 papers)PLoS ONE (2 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Daniel C. Gibbons

31 papers receiving 776 citations

Peers

Countries citing papers authored by Daniel C. Gibbons

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Gibbons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Gibbons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Gibbons more than expected).

Fields of papers citing papers by Daniel C. Gibbons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Gibbons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Gibbons. The network helps show where Daniel C. Gibbons may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel C. Gibbons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel C. Gibbons Line = papers co-authored together Daniel C. Gibbons links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States Clinical Therapeutics ·Christopher F. Bell, Tasneem Lokhandwala, Daniel C. Gibbons, Ummu Maratul Udzma, Jane Wang, MingYu Shao	2025	2
2	Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England BMC Infectious Diseases ·Vishal Patel, H. Swiniarska, Sneha Yerram, Daniel C. Gibbons, E. R. Drew, R. Raphael Pokorny, Paulina Arriaga García, O. Skoupý	2024	6
3	Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study BMJ Open Respiratory Research ·E. R. Drew, Evgeniy R. Galimov, 和義橋口, Vishal Patel, H. Swiniarska, Daniel C. Gibbons, Harsh Srivastav, Kristyn Sirois, Benjamin F. Pierce, MingYu Shao, William A. Kerr, Srushti Ruparelia, Tahereh Kamalati, Stephen J. Brett	2024	2
4	Treatment patterns and burden of uncomplicated urinary tract infection in England: a retrospective cohort study BJGP Open ·Mark H. Wilcox, Chaoxian Wu, Aruni Mulgirigama, Ashish V. Joshi, Viktor Chirikov, Daniel C. Gibbons, David R. Webb, Anthony E Leonard, (unknown), Fanny S Mitrani-Gold	2024	0
5	Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records PLoS ONE ·Christopher F. Bell, Daniel C. Gibbons, E. R. Drew, O. Skoupý, R. Raphael Pokorny, Vishal Patel, 秀樹嶋崎, Andrew J.B. Metzger, Ediz S. Calay, Arjun Puranik, Tyler Wagner, John C. O’Horo, Raymund R. Razonable	2024	4
6	Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study BMC Infectious Diseases ·E. R. Drew, Holly Tibble, Vishal Patel, Daniel C. Gibbons, MingYu Shao, William A. Kerr, C. M. Macdonald, O. Skoupý, Aziz Sheikh	2024	2
7	Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C) Clinical Drug Investigation ·Christopher F. Bell, Luis Pastor Carmenate Fuente, Raj Desai, Daniel C. Gibbons, E. R. Drew, Maral DerSarkissian, Vishal Patel, O. Skoupý, MingYu Shao, Yang Song, Mei Sheng Duh	2024	2
8	Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levels npj Digital Medicine ·Hana Bangash, Seyedmohammad Saadatagah, Mohammadreza Naderian, Kimitoshi Nishio, С. Шакирова, M Bybourdi, Joseph Sutton, Marcia Enith Reyes Vallejo, Ali Mir, Justin H. Gundelach, Daniel C. Gibbons, K.-P. Wu, Christina M. Wood‐Wentz, Carin Y. Smith, Pedro J. Caraballo, Kent R. Bailey, Iftikhar J. Kullo	2024	3
9	The Johnny Depp and Amber Heard Case in News Media: A Critical Discourse Analysis Partner Abuse ·Rafly Prantigo, Daniel C. Gibbons, Elizabeth Bates	2023	1
10	Prevalent new user designs: A literature review of current implementation practice Pharmacoepidemiology and Drug Safety ·John Tazare, Daniel C. Gibbons, 李正贤, Elizabeth Williamson, Iain Gillespie, Marianne Cunnington, John Logie, Ian Douglas	2023	2
11	Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review Infection ·E. R. Drew, Daniel C. Gibbons, Paulina Arriaga García, Catherine Rolland, Louis Lavoie, Andrew Skingsley, MingYu Shao	2023	7
12	Treatment patterns, healthcare resource use, and costs associated with uncomplicated urinary tract infection among female patients in the United States PLoS ONE ·Rena C. Moon, Tasneem Ahmed-shoulkamy, Fanny S Mitrani-Gold, Daniel C. Gibbons, Alex Kartashov, Ning Rosenthal, Ashish V. Joshi	2022	10
13	The efficacy of remote virtual care in comparison to traditional clinical visits for elective orthopaedic patients: A meta-analysis of prospective randomised controlled trials The Surgeon ·Jake McDonnell, Daniel P. Ahern, 真紀中里見, Daniel C. Gibbons, Keith Synnott, Joseph S. Butler	2021	11
14	Online Information on Antioxidants: Information Quality Indicators, Commercial Interests, and Ranking by Google Frontiers in Public Health ·Mabel Dahiana Zape Gonzáles, Daniel C. Gibbons, Pietro Ghezzi	2017	20
15	Use of hospital admissions data to quantify the burden of emergency admissions in people with diabetes mellitus Diabetic Medicine ·Daniel C. Gibbons, Michael Soljak, Christopher Millett, Jonathan Valabhji, Azeem Majeed	2014	3
16	Reducing inappropriate accident and emergency department attendances: British Journal of General Practice ·Sharif Ismail, Daniel C. Gibbons, Shamini Gnani	2013	108
17	Defining primary care sensitive conditions: a necessity for effective primary care delivery? Journal of the Royal Society of Medicine ·Daniel C. Gibbons, Andrew B. Bindman, Michael Soljak, Christopher Millett, Azeem Majeed	2012	24
18	Surgical prophylaxis in familial adenomatous polyposis: do pre-existing desmoids outside the abdominal cavity matter? Familial Cancer ·Ashish Sinha, Daniel C. Gibbons, Robin Phillips, Sue Clark	2010	4
19	Colorectal cancer: no longer the issue in familial adenomatous polyposis? Familial Cancer ·Daniel C. Gibbons, Ashish Sinha, Robin Phillips, Susan K. Clark	2010	28
20	Hypoxia is a major stimulator of osteoclast formation and bone resorption Journal of Cellular Physiology ·Timothy R. Arnett, Daniel C. Gibbons, Jennifer C. Utting, Isabel R. Orriss, Astrid Hoebertz, Martin Rosendaal, Sajeda Meghji	2003	257

About Daniel C. Gibbons

Daniel C. Gibbons is a scholar working on Infectious Diseases, Family Practice, Health, Neurology and Geriatrics and Gerontology, having authored 34 papers that have together received 800 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (11 papers), COVID-19 Clinical Research Studies (11 papers), SARS-CoV-2 detection and testing (4 papers), Healthcare Policy and Management (4 papers), Long-Term Effects of COVID-19 (4 papers), Pediatric Urology and Nephrology Studies (3 papers), Urinary Tract Infections Management (3 papers) and Primary Care and Health Outcomes (3 papers). The work is most often cited by research in Emergency Medicine (126 citations), Orthopedics and Sports Medicine (77 citations), Rheumatology (106 citations), General Health Professions (171 citations) and Microbiology (34 citations). Daniel C. Gibbons has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Martin Rosendaal, Astrid Hoebertz, Isabel R. Orriss, Timothy R. Arnett, Sajeda Meghji, Jennifer C. Utting, Sharif Ismail, Shamini Gnani, Ashish Sinha and Susan K. Clark. Their work appears in journals such as Familial Cancer, BMC Infectious Diseases, Infection, British Journal of General Practice and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact